ScholarWorks@Korea University: Choi, Chul Won

Detailed Information

Choi, Chul Won (최철원)

College of Medicine (Department of Medical Science)

Research Area

Tel 구3058
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Multiple myeloma:7||multiple myeloma:5||Primary myelofibrosis:4||prognosis:4||Polycythemia vera:4||Prognosis:4||Lymphoma:3||Bortezomib:3||Marginal zone:3||Eculizumab:3||autologous stem cell transplantation:3||Chemotherapy:3||Hematopoietic stem cell transplantation:3||Acute myeloid leukemia:3||Treatment outcome:3||diffuse large Bcell lymphoma:3||Micafungin:2||Chronic myeloid leukemia:2||치료:2||Bcell:2||Thrombocythemia, essential:2||Paroxysmal nocturnal hemoglobinuria:2||Imatinib mesylate:2||rituximab:2||진성적혈구증가증:2||Thrombocythemia:2||Rituximab:2||Melphalan:2||본태혈소판증가증:2||Mutation:2||Diffuse large Bcell lymphoma:2||Tcell:2||Myelodysplastic syndrome:2||MDS:2||neutropenia:2||Practice guideline:2||decitabine:2||biosimilar:1||Screening test:1||Nationwide analysis:1||BCRABL:1||Prognostic factors:1||treatment:1||Aplastic anemia:1||bortezomib:1||Granulocyte colonystimulating factor:1||Treatmentrelated mortality:1||Empirical:1||Diagnosis:1||Essential:1||Anthracyclines:1||Neoplasm metastasis:1||Male:1||treatment outcome:1||Galectin3:1||Patients:1||Hepatic venoocclusive disease:1||R CHOP:1||Response:1||Nilotinib:1||JNK:1||hypomethylating agent:1||Surgery:1||imatinib:1||newly diagnosed:1||Decitabine:1||Creactive protein:1||Neutropenia:1||acute lymphoblastic leukemia:1||Imatinib:1||Febrile neutropenia:1||vascular endothelial growth factor:1||Chronic lymphocytic leukemia (CLL):1||Chronic myelogenous leukemia:1||Intravenous access:1||Breast neoplasms:1||유병률:1||endovascular treatment:1||nonHodgkin lymphoma:1||histopathology:1||B cell lymphoma:1||Multiple:1||Bcell lymphoma:1||Thiamine:1||Hodgkin disease:1||BAFF:1||90K:1||Gastric cancer:1||Myeloproliferative disorders:1||EpsteinBarr virus:1||RealWorld Evidence:1||Hydroxyurea:1||BclxL:1||antifungal prophylaxis:1||Hypomethylating agent:1||primary plasma cell leukemia:1||Complement C5 inhibitor:1||aged:1||allogeneic stem cell transplantation:1||일차골수섬유증:1||Complication:1||Sarcoidosis:1||stroke:1||central nervous system:1||NO donor:1||BclXL:1||Essential thrombocythaemia:1||Transcriptome:1||chronic lymphocytic leukemia:1||Diffuse large B cell lymphoma:1||Intolerance:1||invasive fungal infection:1||Immature platelet fraction:1||mobilization:1||LowerRisk Prognostic Scoring System:1||refractory:1||Deferasirox:1||전향적 연구:1||Thalidomide:1||IronDeficiency:1||Pancreatic neoplasms:1||intestine:1||Ovary:1||Hematological diseases:1||Neutropenic fever:1||APRIL:1||5Fluorouracil:1||Incidence:1||Extranodal NK/T cell lymphoma, Nasaltype:1||B cell:1||Polycythemia Vera:1||pegylated granulocytecolony stimulating agent:1||Immune thrombocytopenia:1||Survival:1||essential:1||IPSS:1||Loeffler endocarditis:1||Neutrophils:1||Singleincision technique:1||Platelet count:1||drug therapy:1||combination:1||dasatinib:1||Philadelphia chromosome:1||myelodysplastic syndrome:1||만성 림프구 백혈병:1||Body surface area:1||악성 종양:1||Neoplasms:1||cerebral ischemia:1||endovascular stent:1||Wernicke’s encephalopathy:1||Coronavirus:1||immunomodulatory therapy:1||nomograms:1||RFC regimen:1||Metformin:1||Platelet function analyzer:1||longterm data:1||Modified:1||lenalidomide:1||CD38:1||exosome:1||Inflammatory markers:1||Lymphocytes:1||Complications:1||Neutrophillymphocyte ratio:1||Acute myelogenous leukemia:1||Consolidation chemotherapy:1||Treatment:1||Complete cytogenetic response:1||Aging:1||Subcutaneous port:1||prognostic model:1||Waldeyer's ring:1||breast:1||Diffuse large B cell lymphoma:1||NF kappa B:1||Lymphomas:1||MicroRNA:1||Salvage therapy:1||Bystander:1||pegfilgrastim:1||Paroxysmal Nocturnal Hemoglobinuria:1||Overall Survival:1||posaconazole:1||febrile neutropenia:1||chronic myeloid leukaemia:1||etoposide:1||LRPSS:1||Daratumumab:1||relapsed:1||Chronic myelogenous leukaemia:1||biomarker:1||Pdgfraassociated chronic eosinophilic leukemia:1||Implantable venous access port:1||Young adult:1||Iron chelator:1||진단:1||골수증식종양:1||longterm treatment:1||bone marrow:1||platelet count:1||Induction chemotherapy:1||Cancer patient:1||철 결핍 빈혈:1||Anemia:1||Angioimmunoblastic Tcell lymphoma:1||Gemcitabine:1||Capecitabine:1||Central nervous system:1||immunoglobulin D:1||Granulysin:1||Mucosaassociated lymphoid tissues:1||Pulmonary:1||Posterior leukoencephalopathy syndrome:1||ESHAP regimen:1||ADI:1||Oxaliplatin:1||cereblon:1||Physicians:1||prophylaxis:1||World Health Organization:1||TP53:1||Bleeding:1||Thrombocytopenia:1||radotinib:1||Prednisone:1||Axillary vein:1||minimal residual disease:1||Resistance:1||Myeloproliferative neoplasm:1||Highdose cytarabine:1||Prospective studies:1||Intensive chemotherapy:1||Infection:1||Positronemission tomography:1||남자:1||Prevalence:1||anthracyclinebased chemotherapy:1||observational study:1||Lymphoblastic lymphoma:1||Quality of life:1||Sinusoidal obstruction syndrome:1||Drug Resistance:1||

RSS_1.0 RSS_2.0 ATOM_1.0

145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE